• Hltagconverter 014 - Full Episodes
• Cs 1.6 Spray Maker

BIND-014 (docetaxel nanoparticles for injectable suspension) is being studied in patients with v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation positive or squamous cell non-small cell lung cancer (NSCLC) who have progressed after treatment of one prior platinum-containing chemotherapy regimen. Condition or diseaseIntervention/treatmentPhaseKRAS Positive Patients With Non-small Cell Lung Cancer Squamous Cell Non-small Cell Lung CancerDrug: BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)Phase 2. Layout table for study informationStudy Type:Interventional(Clinical Trial)ActualEnrollment:69 participantsIntervention Model:Single Group AssignmentMasking:None (Open Label)Primary Purpose:TreatmentOfficial Title:An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung CancerStudy Start Date:September 2014Actual Primary Completion Date:April 2016Actual Study Completion Date:April 2016. Secondary Outcome Measures:. Progression-free survival  Time Frame: Change in tumor size will be assessed using RECIST measurements.

RECIST assessments will be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average of 18 weeks. Overall survival  Time Frame: Participants will be followed for survival, an expected average 24 weeks after treatment discontinuation. Duration of response  Time Frame: Change in tumour size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks.

Time to response  Time Frame: change in tumour size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 relative to first dose of study drug. Disease control rate  Time Frame: Change in tumour size will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected average 18 weeks. Safety and tolerability, as measured by number of participants with adverse events. Time Frame: Measured from first dose of study drug until 30 days after study discontinuation.

Objective response rate  Time Frame: change in tumour size will be assessed using RECIST measurements. RECIST assessments will be carried out at baseline, week 6, week 12 and every 6 weeks thereafter relative to first dose of study drug, an expected 12 weeks,. Inclusion Criteria:. Males or females at least 18 years of age.

Hltagconverter 014 - Full Episodes

Diagnosis of NSCLC with locally advanced or metastatic disease. Positive for KRAS mutation or Squamous cell histology. Previously treated with one platinum-based chemotherapy. Disease status must be that of measurable and/or evaluable disease. Performance status of 0 to 1 on the ECOG Scale.

Prior chemotherapy completed at least 3 weeks prior to study enrollment. Prior radiation therapy allowed to.

246.014 SERVICES.The measure of services are:(a) The commissioner of human services shall develop and maintain state-operated services in a manner consistent with sections and and chapters 252, 254A, and 254B. State-operated services shall be provided in coordination with counties and other vendors.

State-operated services shall include regional treatment centers, specialized inpatient or outpatient treatment programs, enterprise services, community-based services and programs, community preparation services, consultative services, and other services consistent with the mission of the Department of Human Services. These services shall include crisis beds, waivered homes, intermediate care facilities, and day training and habilitation facilities.

Cs 1.6 Spray Maker

The administrative structure of state-operated services must be statewide in character. The state-operated services staff may deliver services at any location throughout the state.(b) The commissioner of human services shall create and maintain forensic services programs.

Forensic services shall be provided in coordination with counties and other vendors.